강재헌 교수 연구실
article|
인용수 0
·2022
154TiP AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
Yi-Chang Lu, Youling Gong, Jae‐Heon Kang, J. Whan Ree, X. Chen, Xiao Lin, J. Zhang, Hossein Borghaei
IF 50.5Annals of Oncology
키워드
MedicineMonoclonal antibodyChemoradiotherapyTIGITMonoclonalAntibodyOncologyCancer researchImmunologyInternal medicine